Q4 Financial Results Overview: Addus HomeCare (NASDAQ:ADUS) and Other Companies in Senior Health, Home Health, and Hospice

Quarterly Review: Senior Health, Home Care & Hospice Sector

Quarterly earnings season offers a valuable opportunity to assess how companies are performing, particularly in comparison to others within the senior health, home care, and hospice space. In this overview, we’ll examine Addus HomeCare (NASDAQ:ADUS) alongside other notable players in the industry, highlighting both top and bottom performers.

Industry Overview

Organizations in the senior health, home care, and hospice sectors deliver crucial support to elderly individuals and those with chronic or terminal illnesses. These businesses typically enjoy steady, repeatable revenue streams thanks to long-term relationships with patients and their families. However, the sector faces challenges such as high labor demands, rising staffing costs, and limited profitability due to reimbursement constraints from Medicare, Medicaid, and private insurers. Looking ahead, demographic trends like an aging population and a rise in chronic health conditions are expected to drive demand. The shift toward personalized in-home care, coupled with innovations in telehealth and remote monitoring, should further enhance service delivery. Still, persistent issues such as workforce shortages, wage pressures, and regulatory uncertainties around reimbursements remain hurdles. Embracing digital transformation and technology-driven care models will be essential for sustainable growth.

Q4 Earnings Snapshot

Among the seven senior health, home health, and hospice companies tracked, fourth-quarter results showed modest growth. Collectively, these firms surpassed analyst revenue forecasts by 1.1%.

Despite the revenue beats, share prices across the group have struggled, with an average decline of 6.4% since the latest earnings announcements.

Addus HomeCare (NASDAQ:ADUS)

Addus HomeCare serves around 66,000 clients in 22 states, primarily focusing on individuals eligible for both Medicare and Medicaid. The company specializes in providing in-home personal care, hospice, and home health services to seniors, people with chronic illnesses, and those living with disabilities.

For the recent quarter, Addus HomeCare reported revenue of $373.1 million, marking a 25.6% increase year-over-year. This result aligned with analyst projections, and the company also exceeded earnings per share (EPS) expectations, though the quarter was mixed overall.

Chairman and CEO Dirk Allison commented, “Our fourth quarter capped a year of significant progress and expansion for Addus. Net service revenue climbed 25.6%, and adjusted EBITDA rose 33.3% compared to the same period last year. For the full year, we set a new record with $1.4 billion in net service revenue, up 23.2% from the previous year. Strong demand continues to fuel our growth as more consumers and payers recognize the value and efficiency of our home-based care. Our team’s effective execution has enabled us to scale our proven operating model across the care continuum. Favorable hiring trends, especially in our personal care segment, have also supported our business. We are grateful for our dedicated caregivers who deliver exceptional service to a growing number of patients and families in our markets.”

Since releasing these results, Addus HomeCare’s stock has declined 10.1% and is currently trading at $105.72.

Top Q4 Performer: BrightSpring Health Services (NASDAQ:BTSG)

Established in 1974, BrightSpring Health Services provides a range of offerings including home health care, hospice, neuro-rehabilitation, and pharmacy services.

In the latest quarter, BrightSpring Health Services posted revenue of $3.55 billion, a 16.3% year-over-year increase, beating analyst expectations by 5%. The company delivered a strong quarter, surpassing revenue estimates and providing full-year EBITDA guidance above forecasts.

BrightSpring outperformed its peers with the largest beat relative to analyst estimates. The market responded positively, with shares rising 4.7% since the report, currently trading at $42.03.

Lowest Q4 Performer: Chemed (NYSE:CHE)

Chemed operates two distinct businesses: VITAS, which offers hospice care for terminally ill patients, and Roto-Rooter, which provides plumbing and water restoration services.

Chemed’s quarterly revenue was $639.3 million, unchanged from the previous year and 3% below analyst expectations. The company missed both full-year EPS and revenue estimates, making it the weakest performer in the group this quarter. Shares have dropped 11.8% since the results, now trading at $411.36.

AdaptHealth (NASDAQ:AHCO)

AdaptHealth operates a network of about 680 locations, serving patients in all 50 states. The company supplies home medical equipment and services to individuals managing chronic conditions such as sleep apnea, diabetes, and respiratory illnesses.

For the quarter, AdaptHealth reported revenue of $846.3 million, a 1.2% decrease year-over-year, but still 2.1% above analyst forecasts. The quarter was mixed, with a strong revenue beat but a notable miss on EPS. AdaptHealth also provided the largest full-year guidance increase among its peers. The stock has fallen 5.7% since the earnings release and is now at $9.70.

Option Care Health (NASDAQ:OPCH)

Option Care Health is the largest independent provider of home and alternate site infusion services in the U.S., with 177 locations across 43 states and a team of more than 4,500 clinicians. The company delivers medications and clinical support to patients nationwide.

Option Care Health reported $1.47 billion in revenue for the quarter, up 8.8% year-over-year, matching analyst expectations. However, the company’s full-year revenue guidance slightly missed forecasts, and EPS was in line with estimates. Shares have declined 14.2% since the earnings report, now trading at $30.96.

Looking for Strong Investment Opportunities?

If you’re seeking companies with robust fundamentals, take a look at our Top 5 Quality Compounder Stocks. These businesses are well-positioned for growth, regardless of economic or political shifts.

The StockStory analyst team—comprised of experienced professional investors—leverages data-driven analysis and automation to deliver high-quality, actionable market insights faster than ever before.